Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Brain Res ; 1117(1): 54-60, 2006 Oct 30.
Article in English | MEDLINE | ID: mdl-16996037

ABSTRACT

The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analog of the adrenocorticotropin fragment (4-10) which after intranasal application has profound effects on learning and exerts marked neuroprotective activities. Here, we found that a single application of Semax (50 microg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels accompanying with 1.6-fold increase of trkB tyrosine phosporylation levels, and a 3-fold and a 2-fold increase of exon III BDNF and trkB mRNA levels, respectively, in the rat hippocampus. Semax-treated animals showed a distinct increase in the number of conditioned avoidance reactions. We suggest that Semax affects cognitive brain functions by modulating the expression and the activation of the hippocampal BDNF/trkB system.


Subject(s)
Adrenocorticotropic Hormone/analogs & derivatives , Brain-Derived Neurotrophic Factor/drug effects , Hippocampus/drug effects , Peptide Fragments/pharmacology , Receptor, trkB/drug effects , Administration, Intranasal , Adrenocorticotropic Hormone/chemistry , Adrenocorticotropic Hormone/pharmacology , Animals , Avoidance Learning/drug effects , Avoidance Learning/physiology , Body Weight/drug effects , Body Weight/physiology , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cognition/drug effects , Cognition/physiology , Conditioning, Psychological/drug effects , Conditioning, Psychological/physiology , Dose-Response Relationship, Drug , Exons/drug effects , Exons/genetics , Hippocampus/metabolism , Nootropic Agents/pharmacology , Peptide Fragments/chemistry , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Reaction Time/drug effects , Reaction Time/physiology , Receptor, trkB/genetics , Receptor, trkB/metabolism , Up-Regulation/drug effects , Up-Regulation/physiology
2.
Brain Res Mol Brain Res ; 133(1): 157-61, 2005 Jan 05.
Article in English | MEDLINE | ID: mdl-15661376

ABSTRACT

In most brain areas, uptake of extracellular glutamate predominantly occurs through the glutamate transporter subtype, glutamate transporter-1 (GLT-1), which is enriched in astroglia. Here, we report the identification of five splice variants of the 5'-leader sequence of rat GLT-1 which contain varying numbers of upstream open reading frames and encode putative GLT-1 proteins with two distinct N-terminal modifications. We further demonstrate that the identified rat 5'-GLT-1 splice variants are expressed in a brain region-specific manner. Our findings point to potential influences of RNA splicing on glial glutamate transport in the intact and injured rat brain.


Subject(s)
Alternative Splicing , Excitatory Amino Acid Transporter 2/genetics , Genetic Variation/physiology , RNA Splice Sites/physiology , Animals , Blotting, Northern/methods , Central Nervous System/anatomy & histology , Central Nervous System/metabolism , Exons , Gene Expression , RNA, Messenger/metabolism , Rats , Reverse Transcriptase Polymerase Chain Reaction/methods
3.
J Neurosci Res ; 79(3): 303-9, 2005 Feb 01.
Article in English | MEDLINE | ID: mdl-15605384

ABSTRACT

Severe brain lesions are accompanied by sustained increases in endothelin (ET) levels, which in turn profoundly affect brain microcirculation and neural cell function. A known response of astrocytes to acute increases in ET levels is the rapid and transient closure of gap junctions and the subsequent decrease of gap junction-mediated intercellular communication (GJIC). Because evidence exists that the loss of GJIC alters astrocytic gene expression, we analyzed the effects of chronic ET exposure on astrocytic gap junction coupling. We found that within 24 hr, cultured cortical astrocytes respond to low nanomolar concentrations (2-10 nM) of either ET-1 or ET-3 with a robust inhibition of connexin (Cx)43 expression, the major junctional protein in astrocytes, and a subsequent decline of GIJC. We further observed that in the continuous presence of ETs, Cx43 expression remained inhibited for at least 7 days. In addition, a similar decrease of Cx43 expression occurred in cultured spinal cord astrocytes maintained with ET-1 for 3 days. Applying ETs in combination with the highly selective ETA and ETB receptor antagonists, BQ123 and BQ788, respectively, revealed that the inhibitory influences on astrocytic Cx43 expression depend on activation of ETB receptors. We suggest that the observed ET-dependent inhibition of Cx43 expression and the resulting decline of GJIC might represent a major pathway by which ETs regulate astrocytic gene expression in the injured brain.


Subject(s)
Astrocytes/metabolism , Brain/metabolism , Connexin 43/antagonists & inhibitors , Endothelins/metabolism , Gap Junctions/metabolism , Animals , Animals, Newborn , Astrocytes/drug effects , Brain/drug effects , Cell Communication/drug effects , Cell Communication/physiology , Cells, Cultured , Connexin 43/metabolism , Down-Regulation/drug effects , Down-Regulation/physiology , Drug Administration Schedule , Endothelin A Receptor Antagonists , Endothelin B Receptor Antagonists , Endothelin Receptor Antagonists , Endothelin-1/metabolism , Endothelin-1/pharmacology , Endothelin-3/metabolism , Endothelin-3/pharmacology , Endothelins/pharmacology , Gap Junctions/drug effects , Gene Expression/drug effects , Gene Expression/physiology , Rats , Rats, Sprague-Dawley , Receptor, Endothelin A/metabolism , Receptor, Endothelin B/metabolism , Receptors, Endothelin/metabolism
4.
Brain Pathol ; 14(4): 406-14, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15605988

ABSTRACT

Glutamate is the main excitatory neurotransmitter in the mammalian central nervous system which at high extracellular levels leads to neuronal over-stimulation and subsequent excitotoxic neuronal cell death. Both the termination of glutamatergic neurotransmission and the prevention of neurotoxic extracellular glutamate concentrations are predominantly achieved by the uptake of extracellular glutamate into astroglia through the high-affinity glutamate transporters, excitatory amino acid transporter-2/glutamate transporter-1 (EAAT-2/GLT-1) and EAAT-1/glutamate aspartate transporter (GLAST). Although several injury-induced growth factors such as epidermal growth factor (EGF) and transforming growth factor alpha (TGFalpha) potently stimulate the expression of glutamate transporters in cultured astroglia, GLT-1 and/or GLAST expression temporarily decreases during acute brain injuries eventually contributing to secondary neuronal cell death. We now demonstrate that the stimulatory influences of these injury-regulated growth factors are overridden by endothelins (ETs), a family of peptides also upregulated in the injured brain. Exposure of cultured cortical astroglia to ET-1, ET-2, and ET-3 resulted in a major loss of basal glutamate transporter expression after 72 hours and the complete prevention of the known stimulatory influences of dibutyryl cyclic (dbc)AMP, pituitary adenylate cyclase-activating polypeptide (PACAP), EGF, and TGFalpha on both GLT-1 and GLAST expression. With all ET isoforms, the inhibitory effects were detectable with similar low nanomolar concentrations and persisted in endothelin B-receptor deficient astroglia, suggesting that the inhibitory action is equally induced by endothelin A and B receptors. In astroglial cultures maintained with endothelins alone or in combination with PACAP, the inhibitory action was remarkably long-lasting and was still detectable after 7 days. In apparent contrast, glutamate transporter expression partially recovered between days 5 and 7 in cultures maintained with a combination of ETs and the injury-regulated growth factors EGF or TGFalpha. These findings point to ETs as major mediators of injury-dependent down-regulation of glial glutamate transporters and subsequent glutamate-induced brain damage.


Subject(s)
Endothelins/pharmacology , Excitatory Amino Acid Transporter 2/metabolism , Gene Expression Regulation/drug effects , Neuroglia/drug effects , Amino Acid Transport System X-AG/metabolism , Analysis of Variance , Animals , Animals, Newborn , Blotting, Western/methods , Cells, Cultured , Cyclic AMP/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Endothelins/agonists , Endothelins/antagonists & inhibitors , Endothelins/classification , Enzyme Inhibitors/pharmacology , Epidermal Growth Factor/pharmacology , Excitatory Amino Acid Transporter 2/genetics , Isoquinolines/pharmacology , Nerve Growth Factors/pharmacology , Neuroglia/metabolism , Neuropeptides/pharmacology , Neurotransmitter Agents/pharmacology , Oligopeptides/pharmacology , Peptide Fragments/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction/methods , Sulfonamides/pharmacology , Transforming Growth Factor alpha/pharmacology
5.
Exp Neurol ; 183(1): 124-35, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12957496

ABSTRACT

Injuries to the brain result in the decline of glial glutamate transporter expression within hours and a recovery after several days. One consequence of this disturbed expression seems to consist in the temporary accumulation of toxic extracellular glutamate levels followed by secondary neuronal cell death. Whereas evidence exists that the decline in glutamate transporter expression results from a loss of neuronal PACAP influences on astroglia, the mechanism(s) inducing the reexpression of glial glutamate transporters is presently unknown. We now demonstrate that the injury-induced growth factors EGF, TGFalpha, FGF-2, and PDGF all promote the expression of the glutamate transporters GLT-1 and/or GLAST in cultured cortical astroglia. In contrast, similar stimulatory influences were absent with GDNF and BDNF, growth factors not affected by brain injuries. The effects of EGF, TGFalpha, FGF-2, and PDGF on glial glutamate transport were only partly redundant and involved distinctly different signaling pathways. Unlike EGF, TGFalpha, and FGF-2, PDGF promoted GLT-1, but not GLAST expression and further failed to increase the maximal velocity of sodium-dependent glutamate uptake. Moreover, FGF-2 only affected glial glutamate transport when the RAF-MEK-ERK signaling pathway was concomitantly inhibited with PD98059. Depending on the extracellular growth factor and glutamate transporter subtype, the observed stimulatory effects required the activation of PKA, PKC, and/or AKT. We suggest that after brain injury, reactive processes may limit secondary neuronal cell death by promoting glial glutamate transport. The detailed knowledge of these compensatory mechanisms will eventually allow us to therapeutically interfere with glutamate-associated neuronal cell death in the brain.


Subject(s)
Amino Acid Transport System X-AG/metabolism , Excitatory Amino Acid Transporter 2/metabolism , Gene Expression Regulation/physiology , Growth Substances/physiology , Neuroglia/metabolism , Amino Acid Transport System X-AG/genetics , Animals , Cells, Cultured , ErbB Receptors/metabolism , Excitatory Amino Acid Transporter 2/genetics , Fibroblast Growth Factor 2/pharmacology , Fibroblast Growth Factor 2/physiology , Gene Expression Regulation/drug effects , Growth Substances/pharmacology , Ligands , Neuroglia/cytology , Platelet-Derived Growth Factor/pharmacology , Platelet-Derived Growth Factor/physiology , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Signal Transduction/physiology
6.
Eur J Neurosci ; 16(5): 836-42, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12372019

ABSTRACT

The neuronal cell death associated with certain neurodegenerative disorders as well as acute brain injuries is in part due to the reduced expression of glial glutamate transporters and the subsequent accumulation of toxic extracellular glutamate concentrations. Extracellular factors previously found to potently stimulate the expression of the glial glutamate transporters, GLT-1/EAAT2 and GLAST/EAAT1, in astroglial cultures of rat cerebral hemispheres are PACAP, TGF alpha, and EGF. In the present study, we sought to determine whether similar stimulatory influences apply for astroglia from other areas of the central nervous system (CNS). Immunoblot and real-time RT-PCR analysis of striatal astroglial cultures maintained for 72 h with PACAP, TGF alpha, or EGF revealed a prominent increase in GLT-1 and GLAST expression. In apparent contrast, all factors completely failed to affect GLT-1 and GLAST expression in astroglial cultures from the cerebellum, mesencephalon, and spinal cord between 36 h and 7 days. This failure was not due to the absence of functional recognition or transduction machineries for the extracellular factors as suggested by the additional observations that cerebellar, mesencephalic and spinal cord glia were capable of responding to stimulation with PACAP, TGF alpha, or EGF for 10 min with activation of CREB. Moreover, dibutyryl cyclic AMP (dbcAMP) potently promoted GLT-1 and/or GLAST expression in mesencephalic, cerebellar and spinal cord glia, further indicating that extracellular factors regulate glial glutamate transporter expression throughout the CNS. Together these findings identify PACAP, TGF alpha and EGF as potent regulators of glutamate transporter expression in striatal glia. In addition, these findings provide evidence for a CNS region-specific regulation of glial glutamate transport.


Subject(s)
Amino Acid Transport System X-AG/metabolism , Astrocytes/metabolism , Brain/metabolism , Excitatory Amino Acid Transporter 2/metabolism , Neuroprotective Agents/pharmacology , Spinal Cord/metabolism , Amino Acid Transport System X-AG/drug effects , Animals , Astrocytes/drug effects , Blotting, Western , Brain/drug effects , Cell Culture Techniques , Cerebellum/metabolism , Corpus Striatum/metabolism , Epidermal Growth Factor/pharmacology , Excitatory Amino Acid Transporter 2/drug effects , Mesencephalon/metabolism , Neuropeptides/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Spinal Cord/drug effects , Transforming Growth Factor alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...